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Abstract
Infection with the human immunodeficiency virus (HIV) modifies the course 
of infection by the virus of hepatitis B (HBV) by several mechanisms: the rate of 
chronicity, prolonging viremia by HBV, and increase in morbidity related to liver 
disease. The treatment for both infections should be done in a coordinated manner, 
to avoid the emergence of resistance in HIV, HBV or both, as well as major altera-
tions in the hepatic enzymes. Monotherapies with lamivudine or emtricitabine 
select, rapidly, mutant strains of the HBV and HIV. Monotherapy with adefovir 
has moderate effects in coinfected patients as they already have mutations. If the 
treatment of HBV can defer until the combination antiretroviral therapy of HIV is 
necessary, these patients should receive a combination of tenofovir plus lamivudine 
(or emtricitabine), since this provides a powerful therapy against HBV and estab-
lishes a good central axis for antiretroviral therapy. In addition, it would prevent 
the selection of HBV variant resistance. The influence of HIV in the HCV infection. 
Increase in load HIV-driven viral hepatitis exacerbates hepatic lesions and influ-
ences transmission of the HCV. The risk of sexual transmission increases when HIV 
is present in the carrier. Coinfection modifies the evolution of fibrosis in patients 
with HIV, with higher speed in those who have low CD4 counts, so that the onset of 
cirrhosis occurs before, and the risk of liver decompensation is also more frequent. 
The consequence of this situation is an increase in liver-related morbidity and 
mortality.
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1. Introduction
The hepatitis B virus is one of the most pathogenic and prevalent in the world. 
In some places, up to 95% of those infected with HIV have also been infected with 
hepatitis B, and 10–15% will develop chronic hepatitis B. However, there is a great 
variation for both infections according to the geographical region and the risk 
group. In the USA, it is estimated that 100,000 HIV-infected patients suffer from 
chronic HBV. We do not have data for our country. In patients coinfected with HIV 
and HBV, HBV is less likely to be eliminated. The infection with primary HBV leads 
to chronic hepatitis in 2–5% of immunocompetent adults, while patients infected 
with HIV can become chronic about 5 times more (15–23%). One possible reason is 
the T-cell defect associated with HIV infection.
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HBV and HIV have several characteristics in common even though HBV is a 
double-stranded DNA virus. After entering the hepatocyte, viral DNA is integrated 
into the host genome and the viral RNA is translated by the HBV inverse polymerase 
in new viral DNA and transcribed to viral proteins. The reverse transcription can 
be inhibited by nucleic acid (t) transcriptase inhibitors reverse. The integration 
of the virus into the host’s genome in hepatocytes and CD4+ T cells prevents its 
eradication.
Finally, the mechanisms used to develop resistance are very similar in both 
viruses. All HIV patients should be screened for HBV and HCV. Screening of HIV-
infected patients for HBV must start with the HBsAg application, anti-HBs, and 
anti-HBc. If a positive HBsAg is found, you must complete the study with HBeAg, 
anti-HBe, and HBV DNA. On the other hand, for all patients diagnosed with HBV 
infection, you should have an ELISA for HIV to rule out coinfection.
Like patients monoinfected with HBV with chronic hepatitis B, those coinfected 
with HIV should be evaluated every 6–12 months for hepatocellular carcinoma, 
by measuring alpha-fetus protein and performing an ultrasound of the liver. This 
recommendation is regardless of whether the patient has apparent cirrhosis or not.
The improvement of survival in infected patients by the human immunodefi-
ciency virus (HIV), resulting from the introduction of the therapy powerful anti-
retroviral (“HAART”), has caused chronic liver infections will become important 
causes of hospitalization and mortality in patients infected with HIV (HIV+) [1].
Liver diseases and their consequences represent between 30 and 55% of the 
causes of death in these patients [2]. Frequently, the infection by the viruses of 
the hepatitis B (HBV) and hepatitis C (HCV) is a cause of chronic liver disease in 
patients who are HIV+, which can be attributed to the means of transmission and 
the epidemiological factors among the three viruses [3].
Although the impact of HBV is still not well known in the progression of HIV 
disease, you have to be very clear about the interference of infection by HIV in the 
natural history of HBV infection. Coinfected patients have viral loads of HBV that 
are higher than monoinfected, with a greater risk and a shorter time of evolution to 
cirrhosis [4].
The presence of HIV modifies the natural history of HCV infection, accelerat-
ing the progression of hepatic disease in coinfected people. Of people infected 
with HCV, between 8 and 24% contract cirrhosis in the first 10–20 years after their 
HCV infection [5]. The annual incidence of hepatocellular carcinoma of cirrhosis is 
between 1 and 4% [5].
Works carried out in different countries have shown that the prevalence of HIV/
HBV coinfection ranges between 4.8 and 15% [6–8]. In Brazil, according to previ-
ous studies in various urban areas, the prevalence of chronic hepatitis B in patients 
who are HIV+ ranged between 5.3 and 19.2% [9–12]. Studies conducted in several 
countries reveal that the frequency in the presence of anti-HCV in patients who are 
HIV+ varies between 0 and 42.5% [6–8].
2. Coinfection with hepatitis B in patients with HIV
Hepatitis B, caused by the hepatitis virus B (HBV), is an important problem of 
public health and it is the most serious kind of viral hepatitis. It can cause chronic 
liver disease and carries a high risk of death for cirrhosis and liver cancer. It is 
estimated that in the world there are 2 billion people infected with HBV and more 
than 350 million with chronic liver infection [13].
Coinfection of HBV with the human immunodeficiency virus (HIV) is common 
since they have the same transmission routes.
3Coinfection of Hepatitis B and C in HIV Patients: A Review of the State of the Art
DOI: http://dx.doi.org/10.5772/intechopen.83704
In Western Europe and in the United States, it has been found that 7–10% of 
HIV patients have a chronic infection by HBV, with men who have sex with other 
men being the group with the highest prevalence [14–16]. Patients coinfected with 
HBV and HIV have an increased risk of liver cirrhosis, terminal liver disease and 
death by hepatic pathology, especially in patients with low CD4 lymphocyte counts 
and concomitant use of alcohol [15]. There is a greater risk of hepatocarcinoma and 
adverse hepatotoxic effects in patients using therapy with highly effective antiretro-
viral drugs (TARAE) coinfected with hepatitis B [16].
Ninety-five percent of HBV infections in adults who are healthy are self-limiting 
with an elimination of HBV blood and lasting immunity against the reinfection. 
Chronic infection happens in less than 5% of patients older than 5 years [14, 17]. 
Immunosuppressed patients such as patients with HIV, who are in substitution 
therapy for kidney and diabetics, present a greater risk of chronicity of HBV 
infection [18–20]. Approximately 15% of patients with chronic infection older 
than 5 years can evolve into cirrhosis and hepatic cancer, remaining asymptomatic 
until the appearance of the clinical manifestations of said complications [21]. It is 
estimated that 20% of HIV-positive patients infected with HBV will develop chronic 
hepatitis by this agent [18].
The antigens and antibodies associated with the infection of hepatitis B virus are 
as follows:
A. Surface antigen (HBs Ag): Associated to active infection. Identify patients 
who are infectious and can be detected from 3 to 5 weeks after the infection. 
When it remains more than 6 months high, it is related to chronic infection 
with HBV [22].
B. Antibody against surface antigen (anti-HBs): Its presence indicates in the most 
of the time, immunity for infection with HBV, natural or acquired, as long as its 
value is equal or superior to 10 IU/ml (International Units per milliliter) [23].
C. Antibodies against the core of HBV (anti-HBc): The total anti-HBc is consid-
ered a marker of the previous infection by HBV. Is composed of two fractions: 
anticore IgM, appears at the onset of symptoms, up to 30 days after the appear-
ance of HBs Ag, or during the period in which the biochemical tests liver cells 
are altered in the infection acute and declines between 3 and 12 months after 
the exhibition; anticore IgG, appears during the acute phase of the disease 
associated with HBs Ag and persists throughout life of the individual infected 
with HBV. The presence of anticore IgG can mean: (1) the previous infection 
with immunity, presence of concomitant antibody to the antigen of serum sur-
face greater than 10 IU/ml. (2) in the previous infection with loss of anti-HBs, 
these patients have no evidence neither of viral replication nor of antibodies 
against the surface antigen, because the levels of these antibodies have disap-
peared over time, but reappear after the application of one or more doses of 
the vaccine against hepatitis B.
D. HBV infection hidden, are patients with presence of DNA viral serum or 
liver and absence of HBs Ag and anti-HBs. This situation is not uncommon in 
patients HIV positive, infection with the virus Hepatitis C and in areas of high 
prevalence of infection by HBV.
The infection hidden by HBV may be present in 10–45% of HIV-positive patients 
[24, 25]. Therefore, it is recommended that in all HIV-positive patients the follow-
ing exams for HBV screening are done: HBs Ag, total anti-HBc or anticore IgG and 
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anti-HBs. If the patient has an isolated positive IgG anticore, it is a must to perform 
the viral load of HBV DNA. If a patient has anticore IgG positive in isolation and the 
viral load for HBV is negative, this patient should be vaccinated against hepatitis B 
and he or she could have an anamnestic or primary response [26, 27].
In patients infected with HIV, atypical serological patterns may appear. More 
frequent is the isolated presence of anti-HBc (Table 1), indicative of hepatitis B 
cured with loss of antibodies. Exceptionally, it may be hepatitis hidden B, defined 
by the presence of HBV DNA in liver and serum (viremia will usually be <103 cop-
ies/ml and may be intermittent) in patients with negative HBsAg. In the hidden 
hepatitis B, the markers usually detected are anti-HBc, anti-HBs, and anti-HBe, 
although these markers can be negative (hepatitis B hid seronegative) 4 in most 
patients with hidden hepatitis B, the HbeAg is negative4 (Table 1).
2.1 The course of concurrent hepatitis B and HIV infection
In HIV-positive patients, chronic hepatitis B has an unfavorable evolution 
compared with patients infected only with HBV, and the associated mortality risk 
with hepatopathy is significantly increased. In the MACS study (multicenter AIDS 
cohort study), coinfected patients had an associated mortality to liver disease 8 
times higher than HIV-positive patients HBsAg negative and 15 times greater than 
patients negative for both infections. Mortality associated with hepatopathy due to 
hepatitis B has increased, significantly, since the introduction of the highly active 
antiretroviral therapy (HAART).
In addition to increased mortality, in coinfected patients, HIV accelerates the 
progression of hepatitis B and increases the risk of cirrhosis significantly. It is 
important that the clinician is not fooled by the apparent benign course of hepa-
titis B in HIV patients since this is due to its cellular immunological compromise. 
Frequently, these patients have only one slight increase in transaminases. However, 




HBeAg Anti-HBe AND 
HBV
Acute infection — + + −/+ + — +
Past infection +/− — — + — — —
Asymptomatic 
carrier

















— — — — — — +
History of 
vaccination
+ — — — — — —
Table 1. 
Serologic markers of HBV and clinical interpretation.
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if HBV-DNA is measured, as a marker of viral replication, this is higher in HIV 
patients than in patients who are immunocompetent.
There is a direct correlation between the degree of immunosuppression and 
control of HBV replication in the coinfected patients. Patients with AIDS usually 
show, more frequently, signs of active viral replication. Even in cases with hepatitis 
B, apparently resolved, progressive deterioration of the immune system can lead to 
re-activation of an HBV infection. Most studies on the influence of hepatitis B in 
the evolution of HIV infection have not demonstrated a shortening in survival. The 
infection with HBV does not lead to a faster reduction of cells CD4+ or increase the 
frequency of defining diseases of AIDS. However, some interactions do occur. For 
example, the hepatotoxicity associated with antiretroviral drugs is three times more 
in patients with chronic HBV hepatitis.
2.2 Prevention
All HIV-infected patients who are serologically negative for HBV should be 
vaccinated; this should be done despite the fact that the vaccine may be less effec-
tive in them. Approximately 30% of patients who are HIV positive are primarily 
nonresponsive to the vaccine, against 2.5% of immunocompetent individuals. This 
is especially true for individuals with minor CD4 of 500 cells/mm3. Therefore, for 
these patients, a standard vaccination schedule is recommended. If the patient has 
less than 350 CD4 cells, it is advised to postpone vaccination until after antiretrovi-
ral therapy, and patients should be educated in strategies to prevent the progression 
of liver diseases, such as suppressing consumption of alcohol and tobacco and not 
using herbal supplement (many of which are hepatotoxic).
Standard vaccination against HBV is less effective in infected patients for 
HIV. The administration of four doses of 40 μg (months 0, 1, 2, and 6) improves 
significantly the serological response, and it is the recommended guideline [28].
The consumption of alcohol has an additive effect in terms of progression to 
fulminant hepatitis, development of aggressive chronic liver disease, and develop-
ment of hepatocellular carcinoma. Hepatotoxic drugs must be used very carefully 
and under strict surveillance [29].
2.3 Treatment
HBV-HCV and HBV-HCV-HDV infections are associated with further 
progression of rapid liver fibrosis [30]. The treatment indications for patients 
coinfected with HBV-HCV are the 16, same as for each of the infections sepa-
rately. In patients with multiple infections, there is a predominance of replication 
(VHD > HCV > HBV) that conditions the detection of viral loads of HBV and HCV 
lower than in patients without multiple infections [31].
The suppression of HIV replication and immunological improvement secondary 
to initiation of antiretroviral treatment (ART) is associated with a lower progres-
sion of liver disease, even in patients with decompensated cirrhosis [32].
Therefore, ART is a priority in the care of these patients. In those with preserved 
liver function, any of the drugs recommended in the therapeutic guidelines can 
be used since the risk of severe hepatotoxicity is low. In child B/C stages, protease 
inhibitors (PIs) and raltegravir (RAL) are more secure than NEV or EFV [33].
Dolutegravir [34], etravirine [35], and rilpivirine [36] can be used as there is no 
need to adjust the dose in patients with moderate hepatic insufficiency (child A/B), 
and in advanced stages, some centers monitor the plasma concentrations of the 
drugs and adjust their doses. RAL has demonstrated adequate serum levels without 
the need for dose adjustment and a good tolerance in child [37] stage C patients.
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In coinfected patients with HBV/HIV, tenofovir (TDF) suppresses HBV replica-
tion in most patients and should be part of the ART, and if there are no contrain-
dications, whenever possible, it will be added as second nucleoside analog (t) gone 
[33] TC or FTC.
It must be taken into account that simeprevir (SMV) increases TDF levels and, 
potentially, the risk of nephrotoxicity. In an observational study in patients infected 
with HIV and coinfected with HBV/HDV, the addition of interferon for 48 weeks 
to treatment with TDF (n = 4) was associated with a greater decrease in VHD-RNA 
compared to TDF (n = 13). However, the guideline optimal treatment and response 
monitoring are not well determined and the clinical relevance of the decrease in 
VHD-RNA due to IFN is unknown [38].
3. Coinfection with hepatitis C in patients with HIV
The influence of HIV in the HCV infection. Increase in load HIV-driven viral 
hepatitis exacerbates Hepatic lesions and influences transmission of the HCV. The 
risk of sexual transmission increases when HIV is present in the carrier. This situ-
ation is more evident in the case of homosexual men with multiple sexual contacts 
without using a preservative [39, 40].
In the case of mother-to-child transmission, the risk of transmission to the 
fetus in coinfected women for HIV is between 2 and 5 times higher than in mothers 
monoinfected by HCV and it is between 5 and 25% [41].
Hepatitis C behaves differently in people with HIV, since HIV accelerates the 
evolution of hepatitis C (even so, many people have lived for many years with a 
coinfection for HIV and HCV, often without knowing they were coinfected). The risk 
of significant damage to the liver is greater in people with HIV who have a CD4 count 
below 200 cells/mm3. HCV can be treated, regardless of whether the person is or is not 
infected with HIV. Antiretroviral therapy has reduced notably the number of deaths 
caused by HIV. Currently, liver disease in the terminal stage produced by coinfection 
with HCV has become one of the causes of death rates among people living with HIV 
in certain areas of the United States and Western Europe. In part, this is because HCV 
infection can go undiagnosed until there has already been serious liver damage.
Coinfection modifies the evolution of fibrosis in patients with HIV, with higher 
speed in those who have low CD4 counts, so that the onset of cirrhosis occurs 
before, and the risk of liver decompensation is also more frequent. The consequence 
of this situation is an increase in liver-related morbidity and mortality [42, 43].
It is confirmed that coinfection by the HIV alters the natural history of HCV, 
that increases the risk of can become chronic of HCV, accelerates the progression 
of liver fibrosis associated with VHC [44], increases the risk of decompensation of 
cirrhosis and decreases survival after the first episode of decompensation. On the 
contrary, contradictory data have been published about the impact that HCV can 
have in the natural history of HIV, although does not seem to influence the progres-
sion of clinical events defining AIDS or in mortality [45, 46].
The progression of fibrosis is variable and depends on factors related to the caus-
ative agent and factors related to the host. Among these factors, consumption of 
alcohol, age at acquisition of infection, race, viral coinfections like the concomitant 
infection with HIV, time of infection, body mass index, and various genetic factors 
have been described [22]. Among these, the studies in animals have identified some 
determinant genetic progression of fibrosis; as well in humans, we have tried to 
identify polymorphism genetics to predict the degree of progression in hepatitis C 
and in steatosis of a nonalcoholic liver [47]. Therefore, there are a number of factors 
that you can modify to prevent the progression of liver fibrosis, including alcohol 
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intake and other toxins, the normalization of the index of body mass, and the 
prevention of infections for other hepatotropic viruses.
Hepatitis C does not make HIV worse, but it can complicate your treatment, 
since many drugs to treat HIV metabolize in the liver. Coinfected people have more 
risk of developing hepatotoxicity associated with the antiretroviral treatment than 
those who only have HIV. In any case, the benefits of HIV treatment outweigh the 
risk of hepatic toxicity [48].
HCV screening tests are recommended to all people with HIV. Even if you have 
already been diagnosed with coinfection with HIV and HCV, it is important to know 
how HCV is diagnosed and controlled. Unlike HIV, a positive result in the HCV 
antibody test does not always mean that the person has a chronic infection [48].
HCV screening tests consist of two stages. As usual, first, a test for the detection 
of antibodies against HCV is carried out. If the result is positive, this means that 
you have been infected by hepatitis C before and possibly still have. People who 
eliminated hepatitis C spontaneously without treatment still have the antibodies for 
many years afterwards. On the other hand, in some cases, the results of the anti-
bodies screening tests are negative even when the person has a chronic infection of 
hepatitis C. This can happen if [48]:
• the CD4 cell count is low (usually less than 200), since it is possible that the 
immune system is not producing antibodies; or
• the screening test is performed very shortly after having been infected, since 
antibodies take between 6 and 24 weeks to develop.
An HCV RNA (viral load) screening test is needed to confirm the existence 
of a chronic infection (by HCV). The test of viral load searches for genetic mate-
rial of HCV in the same way that HIV viral load test is used to detect this virus. 
If the quantity of HCV RNA in the bloodstream is detectable, it means that is 
currently infected with HCV. If on the other hand it is undetectable, a second 
test must be performed after 6 months. Yes, if the viral load is not detected in 
two successive tests, it means that the person has eliminated HCV from the body 
(Table 2) [48].
3.1 Prophylaxis
Serology should be performed against HAV and HBV to all adult patients 
infected with HIV, and even more so if infection coexists with HCV in order to 
Diagnosis Previous infection 
and eliminated by 
hepatitis C virus
Acute infection by 
hepatitis C virus
Chronic infection by 
hepatitis C virus
Detection of antibodies Positive Negative, is positive 
6–24 weeks
Positive
Detection of viral load 
(HCV RNA)
Undetectable in two 
tests performed, at 
least 6 months apart
Detectable in 1 or 
2 weeks, usually at 
very high levels
Detectable
ALT test (alanine 
aminotransferase)
It can be normal, 
fluctuate, or show a 
high level of persistent 
way
It can be between 7 
and 10 times higher 
than the normal 
level
It can be normal 
from persistent way, 
fluctuate, or show a high 
level of persistent way
Table 2. 
Diagnosis of HCV and clinical interpretation.
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vaccinate, if appropriate, after having carried out the immunological study. In 
patients with susceptible HIV, the vaccine against hepatitis A will be adminis-
tered in a two-dose schedule separated by 6 months at patients presenting fig-
ures > 200 CD4/ml. With those who are in a degree of older immunosuppression, 
you should wait until your CD4 numbers increase above the 200 cells/ml. There are 
no recommendations about when to perform the revaccination.
The standard vaccination guideline against HBV is three doses intramuscularly 
in the deltoids at 0, 1, and 6 months, which produce immunity greater than 90%. 
The answers are worse particularly among those with lower CD4 [49]. It has been 
postulated that doubling the standard doses or administering another dose could 
produce more adequate protection titles [50]. Patients with CD4 < 200 will proceed 
to vaccination when the figure has increased.
Immunization with the vaccine is lost with time, so controls must be carried out 
later to check the protection. Controls will be carried out between 4 and 12 weeks 
after finishing the vaccination, and more lately once a year.
3.2 Treatment for genotype 1 of hepatitis C
The evidence supports that the beginning of the antiretroviral therapy and, 
therefore, controlling early replication of HIV and maintaining a good immunologi-
cal situation are the first measures to adopt in the coinfected patients. Existing data 
indicate that antiretroviral treatment can slow down the progression of chronic 
HCV liver disease in the coinfected patient, even in the carriers of liver disease, 
increasing their survival [51, 52].
Studies based on liver biopsies have demonstrated a relationship between the 
management of antiretroviral treatment, immunological improvement, and the 
presence of lower grades of hepatic fibrosis [53, 54].
3.2.1 Boceprevir or telaprevir + PR
In patients coinfected with HIV and HCV genotype 1 and without previous 
treatment for HCV SVR after treatment with Boceprevir (BOC) or telaprevir 
(TVR) was higher (63–74%) than in those treated with PR (29–45%) [55, 56].
Efficacy and side effects with both triple patterns were similar to those observed 
in monoinfected patients. The dose of RBV was 800 mg/d in almost all patients. 
Although significant pharmacokinetic interactions have been described, the co-
administration of lopinavir/r, atazanavir/r, and darunavir/r, allowed in the study 
with PR/BOC, did not affect efficacy [55].
The results of the Unite 115 study support the dosage of TVR every 12 h in 
coinfected patients and ART based on IP/r or raltegravir, as well as the possibility of 
shortening the duration to 24 weeks (T12 + PR24) in patients without cirrhosis with 
HCV-RNA undetectable in S4 and S12.
In pretreated coinfected patients, the results of observational studies are similar 
to those obtained in clinical trials with monoinfected patients. The efficacy of these 
guidelines is insufficient in cirrhotic patients or patients with previous response to 
partial or null P/R. Due to its limited efficacy and high toxicity, treatment with BOC 
and TVR should be considered for exceptional use, in patients with genotype 1, 
without treatment or with recurrence prior to PR, when the guidelines considered 
preferred are not available or alternatives:
1. P/R + TVR × 12 s + P/R× 36 s. (AI). If undetectable viral load in s4 and s12, in 
absence of cirrhosis: P/R× 24 s (BI)
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2. P/R× 4 s (lead-in) + P/R + BOC× 44 s (BI)
3.2.2 Sofosbuvir (SOF) + PR
In the study NEUTRINO [57], 291 patients infected with HCV, genotype 1, 
without prior treatment, received treatment with SOF + PegIFN alpha-2a + RBV 
(1000–1200 mg/d) during 12 weeks. Overall, 89% of patients with genotype 1 
reached RVS12: subtype 1a, 92% (207/225); subtype 1b, 82% (54/66). The RVS12s 
was lower in cirrhotic patients (80%) than in noncirrhotic patients (92%).
In a multinational observational study (HCV-TARGET) [58], two thousand and 
sixty-three patients were analyzed treated with guidelines based on SOF, in combi-
nation with PR or with SMV±RBV (in patients with genotype 1) or in combination 
with RBV (in patients with genotypes 2 or 3); 48% were cirrhotic, 52% pretreated, 
and 18% with failure prior to triple treatment with PR + IP. Overall, 5.7% of patients 
had serious side effects (12 patients died and 9 of them were cirrhotic).
In this study, 85% (140/164) of patients with genotype 1 (45% pretreated; 
27% pretreated with PR + IP) treated for 12 weeks with SOF + PR obtained an 
RVS4. SVR4 was higher in noncirrhotic patients (90%) than in cirrhotic patients 
(70%).
In the observational study TRIO [59] (n = 295, with genotype 1), the SVR 12 s 
global in patients without previous treatment (analysis by an intention of treat-
ment) was 77%, without differences between cirrhotic patients (81%; 112/138) 
or not (81%, 25/31). In patients with previous failure (RN: 36%), RVS12 was 
72% (90/125): 76% in noncirrhotic patients (n = 39) and 62% in cirrhotic 
patients (n = 85). Based on the previous regimen, RVS12 was 73% in patients 
with failure prior to IP + PR (n = 40) and 67% in patients with failure prior to 
PR (n = 36). Two percent of the patients abandoned the treatment because of 
side effects.
3.2.3 Simeprevir (SMV) + PR
In the QUEST-1 [60] clinical trials and QUEST-2 [61], the efficacy and safety of 
SMV (150 mg/d) + PR versus placebo + PR for 24 or 48 weeks (according to criteria 
of TGR) in patients monoinfected by HCV genotype 1 without previous treatment, 
the RVS24s overall was 80–81% for SMV + PR and 50% for PBO + P/R. SVR in 
patients infected with HCV subtype 1a with and without the Q80K polymorphism 
in the protease was 58% and 84%, respectively. The SVR obtained by patients 
with subtype 1b was 85% (228/267) globally and 90% (172/192) in the subgroup 
of European patients included in both studies. Depending on the degree of basal 
fibrosis, they reached SVR 84% (317/378) of the patients with fibrosis F0-F2, 73% 
(60/82) with F3, and 60% of the patients with cirrhosis.
A remarkable aspect is the predictive value of the response obtained with this 
guideline in week 4 of treatment. Of the 521 patients who started treatment with 
SMV in the QUEST studies, 78% (404/521) showed an RVR, and of them, 90% 
(362/404) reached RVS12.
In the study TMC435-C212 [62], 106 patients coinfected with HIV/HCV were 
analyzed treated with SMV/PR, with overall RVS12s of 74%; without previous 
treatment (n = 53): 79%; previous relapse (n = 15): 87%; RP (n = 10): 70%; RN 
(n = 28): 57%. Eighty-nine percent of patients without previous treatment or with 
recurrence, he obtained an RVR and of this 89%, he reached RVS12s. Treatment 
with SMV + PR was generally well tolerated, with a tolerability profile and safety 
similar to those shown in monoinfected patients.
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In the PROMISE [63] study, patients monoinfected by HCV with recurrence 
were randomized previously after P/R, to treatment with SMV (n = 260) versus 
placebo (n = 133) during 12 weeks, with P/R (24–48 weeks). The RVS12s was 86% 
(128/149) in patients with subtype 1b and 70% (78/111) in those with subtype 1a 
(78% and 47% in patients without and with the Q80K polymorphism, respec-
tively). Ninety-three percent obtained an RVRe and shortened the total duration of 
treatment at 24 weeks.
In the ATTAIN study [64], the noninferiority of SMV versus TVR was 
demonstrated, in combination with PR, in infected or monoinfected patients 
with partial or no response to RP. Based on the previous response, the SVR 
obtained was: patients with previous RP, 70% (163/234) with SMV versus 68.5% 
(163/238) with TVR; patients with previous RN, 44% (63/145) with SMV versus 
47% (67/146) with TVR10. The risk of anemia was 3 times smaller in those 
treated with SMV, being also of a milder character than that that occurred in the 
TVR group.
3.3 Treatment for genotypes 2 and 3 of hepatitis C
3.3.1 PEGIFN + RBV
In patients coinfected with HIV/HCV genotypes 2/3, the probability of reaching 
an SVR with pegIFN-alpha-2a (180 μg/week) or alpha-2b (1.5 μg g/kg/week) and 
adjusted RBV weight (800–1200 mg/d) for 48 weeks is 62–71% [65, 66].
Patients without cirrhosis who achieve an RVR can be treated for 24 weeks with-
out reduction of response rates [67, 68]. In patients with genotype 2 or 3, without 
previous treatment, due to the lower efficacy and toxicity associated with prolonged 
administration, treatment with PR should be considered for exceptional use, when 
the guidelines considered are not available preferred or alternative:
PR × 48 s (BI). In patients with RVR, PR × 24 s, in the absence of cirrhosis 
(BII).
3.3.2 SOF + RBV
In four clinical studies, phase III, with monoinfected patients with genotype 
2, treated with SOF/RBV for 12 weeks, the SVR ranged between 86 and 97%  
[57, 60, 69]. Also, in the PHOTON 1 [70] studio in patients without prior treat-
ment coinfected with genotype 2, the treatment with SOF/RBV for 12 weeks 
showed an RVS12 of 88% (23/26); in patients pretreated, the SVR after 24 weeks 
of treatment was 92%.
Although the data are inconclusive, pretreated cirrhotic patients could benefit 
from a treatment of more than 12 weeks. In the FUSION study, in patients, the SVR 
was pretreated 60% (6/10) in cirrhotic patients treated for 12 weeks and 78% (7/9) 
in those treated for 16 weeks [60].
3.3.3 SOF + DCV
In study AI444-040 89% (16/18) of the monoinfected with genotype 3, 
without treatment previous, non-cirrhotic, treated with SOF (400 mg/d) + DCV 
(60 mg/d) ± RBV during 24 weeks, he obtained an SVR, with no apparent impact of 
the inclusion or not of RBV in the effectiveness [70].
In the ALLY 3 study, 152 patients infected with HCV genotype 3 were treated 
with SOF 400 mg/d + DCV 60 mg/d for 12 weeks. Overall, they obtained an RVS12 
on 90% (91/101) of patients without previous treatment: cirrhotic: 58% (11/19); 
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without cirrhosis: 97% (73/75). Eighty-six percent (44/51) of the pretreated reached 
RVS12: cirrhotic, 69% (9/13); noncirrhotic, 94% (32/34) [71].
3.4 Treatment for genotype 4 of hepatitis C
3.4.1 PEGIFN ALFA + RBV
Overall, the probability of SVR of patients coinfected with genotype 4 to 
standard treatment with PR is less than 30% (Table 1) 1–5, although it is higher in 
patients with IL28B CC [32].
3.4.2 SOF + PR
We do not have information with the new direct antivirals in patients coinfected. 
In patients monoinfected with HCV, the analysis of patients with genotype 4 
included in the Neutrino7 study showed an RVS12 of 96% (27/28) after 12 weeks of 
treatment with SOF + PR (1000–1200 mg/d).
3.4.3 SOF + RBV
In another study [72] in patients of Egyptian descent, the efficacy of SOF 
400 mg/day + RBV (1000–1200 mg/day) for 24 weeks was greater than the 12-week 
schedule, in patients without previous treatment, 100% (14/14) versus 79% 
(11/14), as in pretreated, 93% (14/15) versus 59% (10/17).
In the Photon 2 [73] study, 84% (26/31) of patients coinfected with genotype 
4, without pretreatment, treated with SOF + RBV for 24 weeks obtained an SVR: 
noncirrhotic 83% (19/23); cirrhotic 88% (7/8).
3.4.4 Interactions between medications
Boceprevir is a potent CYP3A4/5 cytochrome inhibitor. Exposure to medicinal 
products metabolized by CYP3A4/5 may increase when administered with BOC, which 
could increase or prolong its therapeutic effects and adverse reactions. BOC is partially 
metabolized by CYP3A4/5. The joint administration of BOC with drugs that induce or 
inhibit activity of CYP3A4/5 could increase or decrease exposure to Boceprevir [74]. 
Boceprevir is contraindicated when co-administered with drugs whose elimination is 
highly dependent on CYP3A4/5 and in which the elevation of plasma concentrations 
is associated with serious adverse events or they pose a vital risk. This is the case of 
midazolam, triazolam, bepridil, pimozide, lumefantrine, halofantrine, lovastatin, 
quetiapine, alfuzosin, silodosin, and derivatives ergotamines [74].
Telaprevir is partially metabolized by CYP3A and is a substrate of the glycopro-
tein-P (gp-P). Co-administration of Telaprevir with CYP3A-inducing drugs and/
or gp-P can reduce plasma concentrations of TVR. On the contrary, its co-admin-
istration with CYP3A inhibitor drugs and/or gp-P may increase plasma concentra-
tions of Telaprevir. On the other hand, Telaprevir is an inhibitor potent of CYP3A4 
and gp-P. This inhibition is time dependent and can be intensified during the first 
2 weeks of treatment. At the end of the treatment, it may be necessary that approxi-
mately 1 week elapses for the inhibitory effect of Telaprevir to disappear. Telaprevir 
administration can increase the systemic exposure to drugs that are substrates of 
CYP3A or of gp-P, which may lead to an increase or prolongation of its effects and 
risk of adverse reactions [75].
Simeprevir is metabolized by CYP3A4. Therefore, the co-administration of 
Simeprevir with inhibitors of CYP3A4 can increase their plasma concentrations, 
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and in contrast, co-administration of Simeprevir with CYP3A-inducing drugs 
can reduce plasma concentrations of Simeprevir [76]. Its use is not recommended 
combined with other nonanalog reverse transcriptase inhibitor nucleosides [76, 77]. 
The use of SMV with HIV protease inhibitors enhanced or not with ritonavir [77].
Sofosbuvir is a substrate of the gp-P. Therefore, drugs or products that are 
powerful inducers of gp-P (rifampicin, S Juan’s herb, carbamazepine, and phe-
nytoin) can reduce plasma concentrations of SOF and reduce its therapeutic effect. 
The interactions of Sofosbuvir with antiretroviral drugs have been investigated in a 
phase 1 clinical trial conducted in healthy volunteers [78]. Sofosbuvir modified the 
pharmacokinetics of antiretrovirals evaluated within the limits of the prespecified 
equivalency interval [79].
The interaction between Sofosbuvir and recent integrase inhibitors has not been 
evaluated; however, the existence of interactions has not foreseen significant differ-
ences between Sofosbuvir and these drugs [78].
Daclatasvir is a substrate of CYP3A4 and gp-P. Inducers of CYP3A4 and of gp-P 
can reduce plasma levels and the therapeutic effect of DCV. The co-administration 
with potent inducers of CYP3A4 and gp-P is contraindicated, while it is recom-
mended to adjust your dose when used with moderate inductors. Inhibitors of 
CYP3A4 can increase plasma levels of DCV, so it is recommended to adjust their 
dose [80]. Daclatasvir has a scarce influence on cytochrome CYP3A4, so that its 
administration does not affect relevant to the metabolism of antiretroviral drugs 
and, therefore, adjustment of these is not required.
The administration of efavirenz induces the metabolism of daclatasvir reducing 
your AUC by approximately 50%. Therefore, it is necessary to increase the dose of 
daclatasvir at 90 mg/day in case of concomitant use with efavirenz. On the con-
trary, atazanavir/ritonavir increases the daclatasvir by 2.1 times and, consequently, 
it is required to reduce the dose of daclatasvir at 30 mg. Daclatasvir/ritonavir 
increases to a lesser extent the AUC of daclatasvir, by 40%, so it would not require 
dose adjustment of daclatasvir [81]. The dosage of daclatasvir is the same for ATV/r 
or DRV/r that for atazanavir or darunavir powered with cobicistat (COBI); that is, 
the doses of daclatasvir are 30 mg/day co-administered with atazanavir/cobicistat 
and 60 mg/day with daclatasvir/cobicistat [81]. No relevant interactions between 
tenofovir disoproxil fumarate and daclatasvir have been observed [80].
4. Summary of hepatitis C treatment according to the genotype
In Table 3, you can see the summary of hepatitis C treatment according to the 
genotype.
5. Conclusions
The influence of HIV in the HCV infection. Increase in load HIV-driven viral 
hepatitis exacerbates hepatic lesions and influences transmission of the HCV. The 
risk of sexual transmission increases when HIV is present in the carrier. This situ-
ation is more evident in the case of homosexual men with multiple sexual contacts 
without using a preservative [39, 40].
In the case of mother-to-child transmission, the risk of transmission to the 
fetus in coinfected women for HIV is between 2 and 5 times higher than in mothers 
monoinfected by HCV and it is between 5 and 25% [41].
Coinfection modifies the evolution of fibrosis in patients with HIV, with higher 







































Treatment Indications Contraindications Doses
Genotype 
1 (1a or 1b) 
and 4, 5 or 6
Ledipasvir + sofosbuvir Patient with chronic hepatitis C genotype 
1 (1a and 1b), 4, 5, or 6, with the following 
characteristics:
• No cirrhosis or compensated cirrhosis 
(child A) or decompensated (child B and 
C) and
• Without prior treatment or with previous 
treatment with peg-IFN and RBV or with 
previous treatment with inhibitors of 
first-generation proteases (Telaprevir or 
Boceprevir)
• Patient with HIV coinfection and the same 
characteristics considered, taking into 
account the drug interactions and dose 
adjustments according to the antiretroviral
• Patient with genotype 2 or 3
• Patient with chronic renal failure 




1 (1a or 1b) 
and 2 or 3
Daclatasvir + sofosbuvir • Patient with chronic hepatitis C genotype 
1 (1a and 1b), 2, and 3, with the following 
characteristics:
• No cirrhosis or compensated cirrhosis 
(child A) or decompensated (child B and 
C) and without prior treatment or with 
previous treatment with peg-IFN and RBV 
or with previous treatment with inhibitors 
of first-generation proteases (Telaprevir or 
Boceprevir)
• Patient with HIV coinfection and the same 
mentioned characteristics, taking into 
account the drug interactions and dose 
adjustments according to the antiretroviral
Patient with chronic renal failure 

















Patient with chronic hepatitis C genotype 1 
(1a or 1b) with the following characteristics:
• No cirrhosis or compensated cirrhosis 
(child A) and
• Without prior treatment or with previous 
treatment with peg-IFN and RBV
• Patient with HIV coinfection and the same 
mentioned characteristics, taking into 
account the drug interactions and dose 
adjustments according to the antiretroviral. 
Patient with the same characteristics 
mentioned, and with advanced chronic 
renal failure (clearance of creatinine 
<30 mL/min-80 mL/min) or in therapy 
renal replacement
• Patient with genotype 2, 3, 5, or 
6 Patient with decompensated 
cirrhosis (child B or C)
150 mg PTV + 25 mg OBV + 100 mg 
r + 500 mg dasabuvir
Genotype 1b Daclatasvir + asunaprevir • Patients with chronic hepatitis C genotype 
1b with the following characteristics:
• No cirrhosis or compensated cirrhosis 
(child A) and without prior treatment or 
with previous treatment with peg-IFN and 
RBV
• Patient with genotype 1a, 2, 3, 4, 
5, or 6
• Patient with polymorphism of the 
N5SA
• Patients previously treated with 
inhibitors of first-generation prote-








































Treatment Indications Contraindications Doses
Genotype 1 Simeprevir + Ribavarina Patient with chronic hepatitis C genotype 1, 
with following characteristics:
• No cirrhosis or compensated cirrhosis 
(child A) and
• Without previous treatment or with previ-
ous treatment with peg-IFN and RBV
Patient with chronic renal failure 
with creatinine clearance <30 ml/




• - Q80K polymorphism
150 mg SMV + 400 mg SOF
Genotype 2 Sofosbuvir + Ribavarina Patient with chronic hepatitis C genotype 2, 
with the following characteristics:
• No cirrhosis or compensated cirrhosis 
(child A) and
• Without prior treatment or with previous 
treatment with peg-IFN and RBV
• Patient with chronic renal failure 
with creatinine clearance <30 ml/
min
• Patient with anemia
• Caution should be exercised with 
the use of RBV in patients of 
childbearing age, because if it is 
teratogenic, you must wait at least 
6 months after its use to consider 
pregnancy
400 mg SOF + 1000 mg RBV (if the 
patient’s weight is less than 75 kg) or 
1200 mg of RBV (If the weight of the 
patient is greater than or equal to 75 kg)
Genotype 3 Sofosbuvir + Ribavarina + Peg-IFN Patient with chronic hepatitis C genotype 3, 
with the following characteristics:
• No cirrhosis or compensated cirrhosis 
(child A) and
• Without prior treatment or with previous 
treatment with peg-IFN and RBV or with 
previous treatment with SOF + RBV
• Patient with chronic renal failure 
with creatinine clearance <30 ml/
min
• Patient with previous intolerance 
or effects secondary to pegylated 
interferon
• Patient with anemia. Caution 
should be exercised with the use 
of RBV in patients of childbearing 
age, because if it is teratogenic, you 
must wait at least 6 months after its 
use to consider pregnancy
401 mg SOF + 1000 mg RBV + 180 mcg 
peg-IFN (if the patient’s weight is less 
than 75 kg) or 1200 mg of RBV (If the 












Treatment Indications Contraindications Doses
Genotype 4 Sofosbuvir + Ribavarina Patient with chronic hepatitis C genotype 4, 
with the following characteristics:
• No cirrhosis or compensated cirrhosis 
(child A) and
• Without prior treatment or with previous 
treatment with peg-IFN and RBV
• Patient with chronic renal failure 
with creatinine clearance <30 ml/
min
• Patient with anemia
• Caution should be exercised with 
the use of RBV in patients of 
childbearing age, because if it is 
teratogenic, you must wait at least 
6 months after its use to consider 
pregnancy
400 mg SOF + 1000 mg RBV (if the 
patient’s weight is less than 75 kg) or 
1200 mg of RBV (If the weight of the 
patient is greater than or equal to 75 kg)
Table 3. 
Treatment of hepatitis C according to genotype.
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before, and the risk of liver decompensation is also more frequent. The consequence 
of this situation is an increase in liver-related morbidity and mortality [42, 43].
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